Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib

Progress in the systemic control of osteosarcoma has been limited over the past decades thus indicating the urgent clinical need for the development of novel treatment strategies. Therefore, we have recently developed new preclinical models to study promising novel agents for the treatment of pediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Heidler, Christopher L., Roth, Eva K., Thiemann, Markus, Blattmann, Claudia, Perez, Ramon L., Huber, Peter E., Kovac, Michal, Amthor, Beate, Neu‐Yilik, Gabriele, Kulozik, Andreas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384073/
https://www.ncbi.nlm.nih.gov/pubmed/31782150
http://dx.doi.org/10.1002/ijc.32814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384073/
https://www.ncbi.nlm.nih.gov/pubmed/31782150
http://dx.doi.org/10.1002/ijc.32814

Ejemplares similares